JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 908 articles

Articles by James Calloway

Philips Soars on Upgraded Margin Targets and Dividend Plan
Earnings

Philips Soars on Upgraded Margin Targets and Dividend Plan

Philips shares surged over 11% after the company projected stronger profitability through 2026, including an adjusted EBITA margin of 12.5%-13.0% and free cash flow up to €1.5 billion.

Kenvue Shares Steady Ahead of Q4 Report, Merger Timeline in Focus
Earnings

Kenvue Shares Steady Ahead of Q4 Report, Merger Timeline in Focus

Kenvue stock held near $18 in premarket trading as investors await fourth-quarter results on Feb. 17, with no earnings call scheduled due to the pending Kimberly-Clark merger.

KVUE KMB
Hims & Hers Stock Extends Slide Amid Weight-Loss Pill Halt, Regulatory Pressure
Regulation

Hims & Hers Stock Extends Slide Amid Weight-Loss Pill Halt, Regulatory Pressure

Hims & Hers Health shares fell another 4.2% premarket Tuesday, compounding a 16% drop Monday, after discontinuing its compounded semaglutide pill. The company faces a patent lawsuit from Novo Nordisk and potential FDA action.

HIMS
Jumia Shares Slip on Q4 Revenue Miss, Unveils 2026 Targets and Algeria Exit
Earnings

Jumia Shares Slip on Q4 Revenue Miss, Unveils 2026 Targets and Algeria Exit

Jumia's stock fell premarket after reporting Q4 revenue of $61.4M, below estimates. The company outlined 2026 GMV growth targets and plans to exit Algeria in Q1.

Fiserv Shares Gain on Q4 Earnings Beat, Outlook Points to 2026 as Pivotal Year
Earnings

Fiserv Shares Gain on Q4 Earnings Beat, Outlook Points to 2026 as Pivotal Year

Fiserv stock advanced in premarket trading after the payments processor reported quarterly profit above estimates and issued guidance for 2026. The company is navigating a strategic reset following a challenging prior year.

FISV FIS GPN
Datadog Q4 Revenue Tops Estimates, 2026 Outlook in Focus
Earnings

Datadog Q4 Revenue Tops Estimates, 2026 Outlook in Focus

Datadog reported a 29% jump in Q4 revenue to $953M, beating forecasts, but issued a cautious profit outlook. Investors await details on 2026 demand and margins.

DDOG
Upwork Plunges 26% Premarket on Weak Q1 Forecast, Active Client Decline
Earnings

Upwork Plunges 26% Premarket on Weak Q1 Forecast, Active Client Decline

Upwork shares tumbled roughly 26% in premarket trading after issuing first-quarter revenue and profit guidance below analyst expectations. The freelance platform reported a drop in active clients to 785,000 at year-end.

UPWK FVRR
TUI Shares Retreat on Summer Booking Softness Despite Strong Q1 Performance
Earnings

TUI Shares Retreat on Summer Booking Softness Despite Strong Q1 Performance

TUI shares declined as investors focused on a slight dip in summer booked revenue, overshadowing the company's best first-quarter underlying profit in over a decade.

Oscar Health Shares Gain on Upbeat 2026 Forecast Amid Regulatory Scrutiny
Earnings

Oscar Health Shares Gain on Upbeat 2026 Forecast Amid Regulatory Scrutiny

Oscar Health's stock advanced in premarket trading after the insurer projected a return to operating profitability by 2026, despite a wider quarterly loss and a new House subpoena over ACA subsidies.

OSCR
Crypto Kiosk Fraud Prompts Regulatory Crackdown Across U.S. States
Regulation

Crypto Kiosk Fraud Prompts Regulatory Crackdown Across U.S. States

Americans lost over $333 million to cryptocurrency ATM scams in 2025, driving lawmakers in at least 15 states to propose stricter rules including registration mandates and enhanced warnings.

ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
Earnings

ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings

ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.

IBRX MRK
Shopify Shares Gain Ahead of Q4 Earnings as Analysts Adjust Targets
Earnings

Shopify Shares Gain Ahead of Q4 Earnings as Analysts Adjust Targets

Shopify's stock rose over 3% in premarket trading ahead of its quarterly results, with analysts issuing mixed price target revisions. Investors await updates on demand, margins, and AI commerce initiatives.

SHOP